PropertyValue
?:abstract
  • A novel STING agonist, CDGSF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic (\'hot\') tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.
is ?:annotates of
?:creator
?:doi
  • 10.1039/d0cc06959k
?:doi
?:journal
  • Chemical_communications
?:license
  • unk
?:pmid
?:pmid
  • 33331360
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • Medline
?:title
  • A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
?:type
?:year
  • 2020-12-17

Metadata

Anon_0  
expand all